Impact of Respiratory Syncytial Virus
The Nurse’s Perspective

Marianne Bracht,1 Debbie Basevitz,2 Marilyn Cranis3 and Rose Paulley4

1 Neonatal Intensive Care Unit, Mount Sinai Hospital, Toronto, ON, Canada
2 Department of Neonatology, Jewish General Hospital, Montreal, QC, Canada
3 The Hospital for Sick Children, Toronto, ON, Canada
4 Winnipeg Children’s Hospital, Winnipeg, MB, Canada

Contents

Abstract ........................................................................................................... 215
1. What is Respiratory Syncytial Virus (RSV)? ........................................... 216
2. Burden of RSV Disease ........................................................................... 216
3. Risk Factors for Severe RSV Infection ..................................................... 217
4. Strategies for Reducing the Risk of RSV Infection: ............................... 218
   4.1 Education .......................................................................................... 218
   4.2 Reducing Community-Acquired Infection ......................................... 218
   4.3 Reducing Nosocomial Infection ......................................................... 219
5. Outpatient Care for RSV Infection ......................................................... 220
6. Inpatient Care for RSV Infection ............................................................ 220
7. Immunoprophylaxis ............................................................................... 220
8. Strategies for Improving Adherence to Immunoprophylaxis and Preventive Measures ......................................................... 222
9. Potential Treatment Options for RSV Infection in the Future ............... 222
10. Conclusions ........................................................................................... 223

Abstract

Respiratory syncytial virus (RSV) is a highly contagious virus, and is the major cause of lower respiratory tract infections in infants and toddlers worldwide. RSV infection poses serious health risks to young children during the first 2 years of life. Several infant populations have been classified as high risk, and additional risk factors are known to increase the likelihood of severe RSV infection. Treatment for active RSV infection is limited to the symptoms of infection rather than the underlying cause; therefore, it is critical to reduce the transmission of RSV. As nurses, we highlight the importance of educating healthcare professionals, both in the hospital and community settings, as well as parents and other caregivers about the risks and outcomes associated with RSV infection, and necessary measures to decrease the risk of infection. We also highlight the importance of the successful identification of those children who are at high risk of RSV infection. RSV prophylaxis (RSVP) with palivizumab has been shown to improve clinical outcome in infants who are considered high risk compared with those who have not received RSVP. The failure of healthcare staff and primary caregivers to protect children against an RSV infection can have lasting detrimental effects on the health and lives of affected children and their families.
1. What is Respiratory Syncytial Virus (RSV)?

First identified as a human pathogen in 1956,[1] respiratory syncytial virus (RSV) is a single-stranded, enveloped, RNA pneumovirus that infects respiratory epithelial cells in susceptible infants. The F glycoprotein on the surface of the virus participates in viral attachment and mediates the process of fusion between the virus and cell membranes, as well as between infected cell membranes, resulting in ‘syncytia’ formation. There are two subtypes of RSV, type A and type B, which differ in the envelope proteins on the viral shell. Both subtypes circulate annually, and both are infectious; however, there is some evidence that type A is the more common cause of RSV infections[2,3] and may lead to more severe disease.[4] The virus is highly contagious and is the major cause of lower respiratory tract infections in infants worldwide. Nearly all children have been infected by RSV by 2 years of age.[5,6] Autoimmunity to infection in infants is often incomplete and, therefore, reinfection by RSV is common;[7] however, symptoms from subsequent infections are typically less severe.[8] The virus is primarily spread through large particle aerosols (due to coughing or sneezing) or by fomites followed by self-inoculation. RSV can survive on non-porous surfaces for 6–7 hours, porous surfaces such as hospital gowns for 2 hours, and the skin for 20–30 minutes.[9-11] These characteristics make transmission quite likely among children and infants in close contact with each other or with infected caregivers if preventive measures are not strictly followed.

2. Burden of RSV Disease

Although RSV infection often manifests as a mild cold in otherwise healthy adults and can be dismissed as an insignificant nuisance, it can seriously affect many children. It is the leading viral cause of infant mortality, and may cause 7- to 9-fold more deaths than influenza.[12] A recent study by Sampalis[13] demonstrated that hospitalization due to RSV infection leads to increased risk of morbidity and mortality, and increased healthcare resource utilization. The rate of respiratory admissions due to RSV for infants aged <6 months is substantially higher than for any other viral cause, including influenza.[14] Hospitalization for bronchiolitis or pneumonia due to RSV infection can result in additional burdens, such as admission to the pediatric intensive care unit, oxygen supplementation, and mechanical ventilation. Apnea, which may be one of the first signs of RSV disease,[15] is present in 16–20% of young infants. Kneyber et al.[16] also demonstrated that the presence of apnea at hospital admission was related to expression of recurrent apnea and subsequent increased likelihood of mechanical ventilation. In addition, infants or children with active RSV infections may require the cancellation of necessary surgical procedures for underlying medical conditions, specifically those with cardiac anomalies requiring urgent surgery, adding to the risk of additional medical complications. Hospitalization can cause significant disruption of the lives of the families of affected infants, and can lead to increased emotional and financial burdens. The financial burden is not limited to the direct hospital costs for in-patient care and cancellation of scheduled procedures, but also reflects indirect costs such as transportation (which can be substantial for isolated groups), lost wages, food, and daycare for other children in the family.

Adding to the potential cost of infection by RSV is that children with severe RSV infections are more likely to develop ongoing medical problems. Infants hospitalized with RSV infection often have difficulties with feeding, which can persist after recovery from the acute infection.[13] Additionally, Stein et al.[17] demonstrated that hospitalized infants diagnosed with RSV-associated lower respiratory tract infections were 3.2- and 4.3-fold more likely to develop infrequent and frequent wheezing, respectively, by 6 years of age.[17] Sigurs et al.[18] also reported that RSV-associated bronchiolitis in childhood (severe enough to cause hospitalization) was a risk factor for the development of asthma or recurrent wheezing at 13 years of age.[18] Infants with RSV infection are also more likely to need re-hospitalization for respiratory conditions (such as bronchiolitis or pneumonia).
and other conditions (such as anemia or anorexia) after recovery from their initial RSV disease. Older children who had been hospitalized with severe RSV infection as infants are often required to make repeat visits to clinics to address the long-term complications (such as recurrent wheezing and asthma) that occur as a consequence of their earlier RSV infection. These potential additional healthcare and emotional costs add to the overall burden of RSV infection.

3. Risk Factors for Severe RSV Infection

All infants are at risk of RSV disease resulting from infection by the virus; however, certain populations of neonates, medically fragile infants and young children are at higher risk of acquiring severe RSV infection. Premature infants, particularly those of less than 34 weeks' gestation, are at especially high risk, owing to their reduced immune system function and underdeveloped respiratory system. There is also evidence that late preterm (near-term) infants born between 34 weeks' and 36 weeks and 6 days' gestation) are at increased risk. This may partially be due to the fact that while pulmonary function is physiologically premature (inadequate surfactant, incomplete alveolar development, impaired gas exchange), outward physical characteristics (e.g. bodyweight) make these infants appear more like full-term infants. Hence, they may be treated more like full-term infants, rather than being treated with some of the necessary precautionary measures given to other premature infants. While severe RSV infection has most often been associated with younger age (<6 months), there is emerging evidence that the prevalence of acute lower respiratory infection caused by RSV is increasing in relatively older, more mature infants (aged 6–11 months).

Infants and toddlers suffering from chronic lung disease and congenital heart disease (CHD) have a higher risk of hospitalization and fatality resulting from RSV infections, as do children with cystic fibrosis and pulmonary hypoplasia. Down syndrome, neuromuscular disease, and severe immune system compromise. The presence of these severe underlying co-morbid conditions, including malignancies, is associated with mortality among term and older children with RSV infection. It also appears that boys have a higher risk of having complications associated with RSV infection than girls. This may be due to the narrower and shorter airways relative to lung size in boys, resulting in lower levels of airway conductance, which in turn makes airway obstruction from respiratory tract infection more common. Generally, birthweight contributes to risk, as infants with low birthweight for their gestational age are more likely to have complications associated with RSV infection. While a high percentage of these 'high-risk' children are hospitalized due to complications from severe RSV infection, a higher overall percentage of hospitalized children derive from non-high-risk groups. This highlights the importance of educating all parents and healthcare staff about the transmission of RSV, since it applies to all infants and children, not just to those considered 'high risk.'

There are additional risk factors that increase the susceptibility of newborns to RSV infection (see table I). In northern latitudes, the 'RSV season'

| Table I. Factors that contribute to increased risk of severe respiratory syncytial virus (RSV) infection |
|---------------------------------------------------------------------------------------------------------------|
| **Premature birth**[21-23] |
| Chronic illness/disease[25,32] |
| Chronic lung disease,[25,32] hemodynamically significant congenital heart disease[25,32] |
| Cystic fibrosis and/or pulmonary hypoplasia[26,27] |
| Down syndrome[28] |
| Neuromuscular disease[29] |
| Severe immune compromise[29] |
| Male sex[30] |
| Low birthweight for gestational age[23,33] |
| Young chronologic age (<12 weeks at start of RSV season)[34-36] |
| Attendance in daycare centers[36-38] |
| Presence of pre-school or school-aged sibling(s)[35-37,39] |
| High number of people in home or multiple people sharing a bedroom[38,40] |
| Not breastfeeding[37] |
| Exposure to tobacco smoke[41,42] |
| Family history without eczema[43,44] |

Specific risk factors may vary in impact depending on geographic region and ethnic population.
typically runs from early winter (November/December) through late spring (April/May). It is during this time that the rate of hospitalization due to RSV infection is highest,[14] making this a particularly important time for caregiver vigilance and appropriate prevention measures. However, it has been demonstrated that RSV infections can occur at any time of year,[21,45] highlighting the importance of year-round education and infection reduction measures. Other risk factors that may increase an infant’s susceptibility to RSV were reviewed by Simoes,[37] and include attendance in daycare and having pre-school or school-aged sibling(s). Also, higher numbers of people sleeping in the same room has been shown to increase the risk of hospitalization due to respiratory tract infection.[38,40] It is generally thought that breastfeeding confers some protection against RSV-associated lower respiratory tract infection,[37] such that children who are not breastfed are at increased risk. The air quality within the home is of importance as well; exposure to tobacco smoke may cause increased respiratory tract reactivity in susceptible infants, leading to exacerbation of respiratory disease.[41,42]

4. Strategies for Reducing the Risk of RSV Infection

4.1 Education

Due to the severity of RSV disease, and the ease with which the virus is transmitted, an education program for all healthcare providers, including parents and other caregivers, should be a priority (see table II). For primary caregivers, the focus needs to include the identification of those children at risk of severe RSV disease, the characteristics of the virus itself, the mode of virus transmission, and the symptoms of infection, regardless of the risk status of children. Education sessions should also include demonstrations of diligent hand washing, as hand hygiene is a crucial element in infection control. Traditionally, hand washing has been performed with soap and water; however, alcohol-based hand rinses and gels have been shown to be effective in removing microorganisms from hands (reviewed by Boyce and Pittet[46]). Additionally, information should be provided on proper disinfecting of susceptible surfaces and other areas where RSV can be found. Because of its potential to reduce the risk of RSV susceptibility (and provide other health benefits), breastfeeding should be encouraged. Education about the potential consequences of severe RSV disease, including its contribution to persisting health problems, is highly important. Education points for reducing the risk of RSV transmission are outlined in table II and specifically addressed in sections 4.2 and 4.3.

4.2 Reducing Community-Acquired Infection

In the community setting, children at risk of RSV infection are typically healthier (not requiring hospitalization), but are being cared for in clinics and doctors’ offices where prevention guidelines and practices may be less rigorous or non-existent (such as in waiting rooms). In an outpatient clinic or doctor’s office, minor cold symptoms may often be ignored, as RSV may not be as prominent in the minds of those who are tending to children, specifically those children

Table II. Measures to reduce respiratory syncytial virus (RSV) transmission

| **In the hospital/clinic** |
|----------------------------|
| Hand hygiene: wash hands thoroughly with soap and warm water before and after touching children. Hand sanitizer can be used if hands are not soiled |
| Wear gloves, gowns, masks |
| Promptly identify all persons (patients, parents, and others) with febrile respiratory illness in outpatient areas |
| Effectively isolate or cohort any infant(s) or child(ren) with cold symptoms (cough, runny nose) even if not yet diagnosed with RSV |
| Promptly screen/test for RSV |
| Routinely disinfect susceptible surfaces, including toys and books, in waiting rooms of offices and clinics |

| **In the home** |
|-----------------|
| Hand hygiene: wash hands thoroughly with soap and warm water before and after touching children. Hand sanitizer can be used if hands are not soiled |
| Frequently wash children’s clothes, bedding and toys |
| Keep children away from crowded areas and from those who are sick |
| If parents are sick, minimize close contact with children (avoid kissing) |
| Encourage and support breastfeeding |

© 2011 Bracht et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (3)
who do not have the significant risk factors listed above. Additionally, it has been demonstrated that during RSV outbreaks, infection of medical staff is common, and the symptoms of such infections can be dismissed as being caused by mild colds or flu-like illnesses. Indeed, caregivers who have active RSV infections may even be asymptomatic.

The attention to diligent hand washing before and after contact with patients cannot be overstated for reducing the risk of community-acquired RSV infection. In outpatient clinics and doctors’ offices, it is important for staff to wear gloves, gowns, and masks, and to make every effort to immediately isolate any patient with cold symptoms in an assessment room. It is also recommended to routinely disinfect susceptible surfaces (including toys and books) in waiting rooms. It may be best to remove toys and books from waiting rooms altogether and encourage families to bring their own toys, if needed. In the home, primary caregivers should be instructed to keep their children away from large crowds, areas where people are sick, and areas where the children may be exposed to tobacco smoke. When parents are sick, they should make every attempt to minimize close contact with the children and avoid kissing.

4.3 Reducing Nosocomial Infection

Another important consideration regarding the risk of infection by RSV is the potential for nosocomial transmission. Welliver et al. recently reviewed the impact of nosocomial infection, noting a study by Langley et al. in which a 10-fold higher mortality rate was found in children with nosocomial infection compared with those with community-acquired infection. The risk of nosocomial transmission may be higher in children who are being cared for in a hospital’s neonatal unit or pediatric ward due to the already compromised health of the child (neccessitating hospitalization), and the high density of patients and number of staff. RSV transmission may occur even though there may be standard prevention guidelines in place in such settings. This risk may be increased due to a delay in detecting and diagnosing RSV infection in infants. Symptoms of RSV infection, such as apnea, bradycardia, and changes in ventilation, can often be attributed to causes other than RSV. The ability to quickly identify those infants who may have an RSV infection can decrease the risk of nosocomial transmission. In addition to the increased mortality risk, RSV infection in hospitalized children can severely impact their health status, and subsequently prolong hospital stays.

To reduce the likelihood of nosocomial transmission, it is recommended to have an annually updated, readily available, written policy for hospital and clinic employees to follow, outlining the important preventive steps. Hospital staff should be educated about how to avoid RSV exposure (by wearing gloves, gowns, masks, and, where necessary, protective eyewear), and on the importance of maintenance of hand hygiene by thorough washing immediately before and after contact with all children. It is a good idea to conduct these training sessions just prior to the start of the annual RSV season. Screening protocols for early RSV identification should be in practice in neonatal and pediatric care facilities. Hospitals should have a policy of immediately isolating or cohorting infants who display cold symptoms. In the ideal situation, infants should be isolated and tested for the pathogen causing the cold symptoms. Children should then be grouped by underlying pathogen once it has been identified (to reduce the likelihood of coinfection). However, not all hospital facilities are equipped to quickly diagnose the underlying cause of symptoms, or have the space to isolate each individual child. In these cases, it is best to immediately cohort children based on symptoms. A demonstration of the effectiveness of these measures to control the spread of RSV among hospitalized infants was reported by Isaacs et al. These authors showed that when the prevention protocol was rigorously followed, RSV infection contracted while in the hospital decreased from 4.2% to 1.1% in non-CHD infants, and from 34.8% to 3.3% in infants with CHD. An added benefit of the implementation of these measures is the potential to decrease the transmission of other infective agents. Attention to
these steps can help reduce the number of children who develop severe RSV disease.

5. Outpatient Care for RSV Infection

The responsibility for outpatient care of patients with RSV infection rests with the primary caregivers as well as physicians and nurses in offices and clinics. Therefore, one of the key priorities for outpatient care, in order to minimize the likelihood of RSV infection, is the education of the primary caregiver. This teaching should include information on factors that contribute to increased risk (table I). Additionally, there should be a focus on the steps that can be taken to minimize the risk of RSV transmission (highlighted in sections 4.2 and 4.3, and in table II). The next step in outpatient care is the education of the primary caregivers about the signs and symptoms of RSV infection. Infection will typically present as a mild upper respiratory tract illness with symptoms such as low grade fever, cough, nasal congestion, vomiting, diarrhea, and decreased food intake. Moderate symptoms include apnea (which may be the first symptom in premature and/or very young infants[15]), irritability, tachypnea, increased coughing and wheezing, diaphoresis, and dehydration. The disease can progress to a lower respiratory tract infection with severe symptoms of respiratory distress, including lethargy, apnea, tachypnea, wheezing, nasal flaring, grunting, retractions, and cyanosis. Importantly, not all infected children will necessarily demonstrate the same symptoms, which can make diagnosis difficult. For example, apnea is more common in preterm, younger infants without fever.[51] It is important to educate caregivers about these common symptoms so that they can alert the child’s physician promptly upon their appearance. If symptoms are sufficiently severe, or if there are signs of worsening symptoms, the physician may recommend admission to an inpatient facility.

6. Inpatient Care for RSV Infection

Many treatment approaches, as recently succinctly reviewed by Paes et al.,[52] have been utilized in patients with active RSV bronchiolitis. Treatment with corticosteroids, including dexamethasone, prednisone, and inhaled corticosteroids, has not resulted in clear improvements (reviewed by Mitchell[53]) and is therefore not recommended. Additional approaches have included the use of leukotrienes and ribavirin; however, they are also not recommended due to a lack of evidence for improving clinical outcomes.[53,54] Ribavirin, an agent with broad-spectrum antiviral activity, had previously been used to treat active infection, but limited clinical effectiveness and potential risks to patients and staff have led to decreased use.[55] Bronchodilators can be used on an individual basis; however, their use should be continued only if there is evidence for therapeutic benefit.[53] Antibiotics should be used only when there is a strong suspicion of bacterial infection, and should be stopped when cultures are shown to be negative.[53] There is no evidence of positive therapeutic benefit of antibacterial treatment for bronchiolitis. As a result, treatment of RSV bronchiolitis currently focuses on supportive care, including the administration of supplemental oxygen when oxygen saturation is below 90%, maintenance of fluid balance, and nutrition. When necessary, mechanical ventilation with or without extracorporeal membrane oxygenation is used to maintain adequate oxygenation.

7. Immunoprophylaxis

The only currently available pharmacologic prophylactic to decrease the risk of RSV infection is palivizumab, a passively used monoclonal antibody utilizing a humanized monoclonal antibody specific for the F protein of both subtypes of RSV.[56,57] A pivotal clinical trial conducted in children at high risk of RSV infection demonstrated a significant reduction in RSV-related hospitalization rate in those who received RSV prophylaxis (RSVP) with palivizumab, in addition to a decreased length of stay in the hospital, lower incidence of admission to the intensive care unit, fewer days with increased supplemental oxygen, and fewer days with moderate or severe lower respiratory tract illness compared with those who received placebo.[58] Results support-
ing this initial trial have been obtained by other researchers. Feltes et al. also demonstrated the ability of RSVP to reduce hospitalization rates in children aged ≤24 months with hemodynamically significant CHD. Primary adverse effects associated with palivizumab therapy are local erythema, pain at the injection site, upper respiratory infection, fever, and rash, with very rare cases of anaphylaxis reported. Because of its positive benefit and adverse-effect profile, palivizumab has been approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. While it has been shown to be effective as a prophylactic measure, palivizumab does not appear effective in reducing the severity of active RSV infections. However, if infants contract RSV while receiving palivizumab injections, RSVP should continue for the remainder of the RSV season, as RSV infection does not confer complete immunity; thus, continuation of RSVP may help to prevent reinfection in the same year.

One of the difficulties in the use of RSVP to decrease RSV infection is the determination of ‘high-risk’ infants. Using the risk factors outlined in table I, guidelines have been developed to determine which children qualify for RSVP. These guidelines may vary depending on the specific country and region, and healthcare staff should contact a regional health authority to determine the approved qualifications for RSVP. There may be certain populations who are at particular risk for RSV disease due to their geographic isolation or ethnic susceptibility. For example, in Canada, Inuit populations are highly susceptible to severe RSV infection, and infections are common throughout the year; therefore, each province in Canada has slightly different guidelines for those children who qualify for RSVP.

The approved administration schedule for RSVP is based on the clinically validated regimen reported by the IMpact-RSV Study Group and includes monthly intramuscular injections throughout the RSV season. In many cases, the first injection (and sometimes subsequent injection) is given in the hospital setting, with the completion of the RSVP regimen occurring in outpatient doctors’ offices or specialized RSV clinics. Importantly, to date, it appears that palivizumab can be administered along with other scheduled vaccines without affecting their immunogenicity. However, if a reaction were to occur with coadministration, it would be difficult to determine the cause.

When given monthly as recommended, blood concentrations of palivizumab are sufficient to help improve clinical outcome measures in high-risk infants. However, just prior to the second administration, trough serum antibody levels are the lowest that they will be over the course of RSVP. Missing or delaying a dose of palivizumab will cause the antibody level to drop further and potentially increase susceptibility to RSV infection. Therefore, it is essential that subsequent doses of palivizumab be administered at the scheduled time to ensure that antibody titers are maintained at an effective level. Additionally, it has been shown that children requiring cardiopulmonary bypass for cardiac surgery show significant decreases in serum palivizumab concentrations after surgery. It is recommended that these children receive a dose of palivizumab as soon as possible after surgery to promote effective prophylaxis. Achieving and maintaining target serum palivizumab concentrations may not confer protection for all infants; furthermore, it is possible that the diminished trough serum concentration of palivizumab prior to its second administration may increase the susceptibility of infants to RSV infection. Therefore, increased vigilance and adherence to the approved timeline for RSVP and to other prevention measures may improve the clinical outcome of high-risk infants.

In addition to the effectiveness of palivizumab as a means of reducing the occurrence and severity of RSV infection in high-risk infants, RSVP has also been associated with lower rates of recurrent wheezing by the time children have reached 2–5 years of age. In addition to this important effect on the well-being of the infected infants, successful RSVP may also provide benefits for the infants’ primary caregivers. The reduction in duration of moderate or severe lower respiratory tract illness and potential hospitalization results in less time off work (and associated
decrease in income), may help reduce trans-
portation and food costs associated with hospital
visits, and may also help reduce the need for al-
ternate care for siblings of the affected infant.
However, these potential benefits need to be
weighed against the costs associated with RSVP.
One recent report has shown that the hospital-
ization rate due to RSV infection for high-risk
infants (aged 0–6 months) ranges between 8%
and 56%, compared with 4.4% of infants who are
considered low risk.[67] Even with this relatively
high rate of hospitalization due to RSV infection,
economic cost-benefit analyses have yielded
conflicting results.[68–70] Recent Canadian studies
have reported that the cost effectiveness of RSVP
for infants of 33 to <36 weeks’ gestation was best
achieved when the Canadian risk-scoring tool
was used. The risk assessment tool provides the
nurse or doctor with a practical and efficient way
of identifying infants who are at low risk of ac-
quiring RSV, therefore excluding them from
RSVP - a subsequent cost saving.[71,72]

This highlights the need for appropriate deter-
mination of true high-risk infants to implement
the most cost-effective strategy for passive im-
munization while maintaining the highest possible
rates of effective RSV disease prevention. How-
ever, since children who score low on risk-
assessment measures may go on to develop severe
RSV disease, attention to risk-reduction tech-
niques is also of critical importance.

8. Strategies for Improving Adherence to
Immunoprophylaxis and Preventive
Measures

We feel that the best way to improve adher-
ence to preventive measures is to educate all those
who are in direct contact with susceptible chil-
dren about the basic characteristics and common
modes of RSV transmission and prevention. This
education can take the form of in-service educa-
tion, ‘lunch-and-learn’ sessions, and/or seminars
for doctors and nurses. Posters that demonstrate
ways to decrease the risk of infection can be dis-
tributed throughout healthcare facilities and doc-
tors’ offices. Parents and other caregivers may
need individual education and counseling as well
as information pamphlets that reinforce the
necessary risk-reduction information. Essential
topics for education are the specific ways to de-
crease risk of transmitting RSV (see table II), and
the necessity of adhering to the timelines for
RSVP in children who qualify for immuno-
prophylaxis. An important step is the successful
education about the long-term consequences that
can arise from the failure to adequately protect
children from severe RSV infection. We propose
that these education sessions occur just prior to
the start of each annual RSV season, reinforcing
the benefits of adhering to prevention protocols,
in order to maximize adherence throughout the
RSV season.

One additional way to improve the adherence
of parents and caregivers when the infants leave
the hospital is to ensure that there is effective
communication of medical and any other pertinent
information between the parents and healthcare
provider regarding scheduled immunoprophylaxis
requirements. Obtaining sufficient and accurate
contact information for the parents of discharged
infants allows clinic nurses and doctors’ offices
to initiate calls to remind families of upcoming
appointments for subsequent administrations of
RSVP. Also, providing families with an appoint-
ment card for the next appointment including
date, time, and office phone number, as well as
encouraging families to call should they have any
questions or concerns, improves the likelihood of
successful adherence. It is critically important that
families understand the impact of RSV disease so
that they can better advocate and follow through
with the necessary risk-reduction measures.

9. Potential Treatment Options for RSV
Infection in the Future

There are currently several treatment approaches
being investigated for RSV infection, as recently
reviewed by Empey et al.[62] These treatments
target different proteins associated with the rep-
ication and/or infection processes of the virus.
While these novel treatments are promising, they
are either in preclinical development or early
clinical trials, suggesting that, even if successful,
they will not be clinically available for years to come.

The promise of a vaccine for RSV has been a discussion point for primary care providers for some time. Unfortunately, due to several factors, a safe and effective RSV vaccine has yet to be developed. One primary factor contributing to the unsuccessful development of a vaccine to date is that the targeted population for the RSV vaccine consists of young infants from birth to 6 months of age. These infants may have an inadequate response to vaccination due to their underdeveloped and under-responsive immune systems, and because of the potential for suppression by maternally transmitted antibodies.[73] A vaccination attempt in the 1960s using inactivated RSV resulted in an exaggerated response to the virus, followed by the hospitalization of 80% of the vaccinated infants and two deaths.[74] This result has hampered the development and testing of novel vaccine approaches.

New approaches to vaccine development are exploring the use of live, attenuated viruses, administered to infants intranasally.[75] Administration directly to the nasal mucosa induces local and systemic immunity, and also minimizes suppression by maternally transmitted antibodies. Intranasal administration may also confer greater protection and higher immunogenicity. Ensuring a balance between immunogenicity and successful attenuation of live virus is of critical importance to the successful development of an RSV vaccine. There are currently several early clinical trials that are aimed at examining the safety and immunogenicity of novel vaccines.

10. Conclusions

RSV infection poses a serious health risk to young infants and children, particularly during the first 2 years of life. There are several categories of patients who are considered to be at high risk of developing severe RSV infection, and additional environmental factors may also contribute to the risk of developing severe RSV disease. Severe RSV infection may be associated with persistent and recurring health problems for children, highlighting the need to reduce the rate and severity of infection. Education of parents, hospital staff, and nurses who are responsible for the direct care of susceptible children is of critical importance to reduce the transmission of RSV. Education should focus on the characteristics of RSV, routes of transmission, and proper techniques for reducing the risk of transmission. While treatment of active RSV infection is limited and restricted to the symptoms of infection, high-risk infants given palivizumab immunoprophylaxis have a decreased rate of hospitalization and fewer days with moderate or severe lower respiratory tract illness compared with those who do not receive therapy. Identification of eligible infants is critical to the successful implementation of immunoprophylaxis. Effective education and risk-reduction techniques are crucial to minimize infection of young children by RSV and to help to reduce the burden of the disease.

Acknowledgments

No financial support was provided to the authors for the development of the manuscript. Marianne Bracht, Marilyn Cranis, and Rose Paulley have received support from Abbott, Ltd., Canada, in the form of unrestricted educational grants in sponsorship of their respective institutional RSV programs. Marianne Bracht, Marilyn Cranis, and Rose Paulley have received honoraria and/or travel support for presentations at Abbott-sponsored nurses’ meetings. Debbie Basevitz has no conflicts of interest to declare. Medical writing support was provided by Nathan R. Rustay, PhD, an employee of Abbott.

References

1. Morris JA, Blount Jr RE, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956 Jul; 92 (3): 544-9
2. Mufson MA, Belshe RB, Orvell C, et al. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J Infect Dis 1988 Jan; 157 (1): 143-8
3. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1988 Jan; 157 (1): 143-8
4. Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006 Jan 1; 193 (1): 54-8
5. Henderson FW, Collier AM, Clyde Jr WA, et al. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979 Mar 8; 300 (10): 530-4
6. Simoes EA. Respiratory syncytial virus infection. Lancet 1999 Sep 4; 354 (9181): 847-52
7. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986 Jun; 140 (6): 543-6

8. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001 Jun 21; 344 (25): 1917-28

9. Blydt-Hansen T, Subbarao K, Quennec P, et al. Recovery of respiratory syncytial virus from stethoscopes by conventional viral culture and polymerase chain reaction. Pediatr Infect Dis J 1999 Feb; 18 (2): 164-5

10. Bracht M, Heffer M, O’Brien K. Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program. Adv Neonatal Care 2005 Feb; 5 (1): 39-49

11. Hall CB, Douglas Jr RG, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980 Jan; 141 (1): 98-102

12. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8; 289 (2): 179-86

13. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003 Nov; 143 (5 Suppl.): S150-6

14. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 2006 Sep; 25 (9): 795-800

15. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection: a systematic review. Crit Care 2006; 10 (4): R107

16. Kneyber MCJ, Brandenburg AH, de Groot R, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr1998; 157 (4): 331-5

17. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999 Aug 14; 354 (9178): 541-5

18. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005 Jan 15; 171 (2): 137-41

19. Hislop AA, Hawarth SG. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation. Am Rev Respir Dis 1989; 140: 1717-2

20. Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and “small-for-dates” newborn babies. Lancet 1968 Jun 1; I (7553): 1167-70

21. Coffman S. Late preterm infants and risk for RSV. MCN Am J Matern Child Nurs 2009 Nov-Dec; 34 (6): 378-84

22. Engle WA, Tomashke KM, Wallman C. “Late-preterm” infants: a population at risk. Pediatriics 2007 Dec; 120 (6): 1390-401

23. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003 Nov; 143 (5 Suppl.): S127-32

24. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010 May 1; 375 (9725): 1545-55

25. Welliver RC, Checchia PA, Bauman JH, et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010 Sep; 26 (9): 2175-81

26. Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998 Dec; 26 (6): 371-9

27. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999 Oct; 18 (10): 866-9

28. Bloomers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis – a prospective birth-cohort study. Pediatrics 2007 Oct; 120 (4): e1076-81

29. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009 Sep; 10 (3): 148-53

30. Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988 Oct 27; 319 (17): 1112-7

31. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr 1995 Feb; 126 (2): 212-9

32. Synagis® [package insert]. Gaithersburg (MD): MedImmune, LLC, 2010

33. Cilla G, Sarasa A, Montes M, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 2006 Jun; 134 (3): 506-13

34. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001 Sep; 20 (9): 874-9

35. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004 Sep; 23 (9): 806-14

36. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003 Nov; 143 (5 Suppl.): S118-26

37. Anderson LJ, Parker RA, Strikas RA, et al. Day-care center attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988 Sep; 82 (3): 300-8

38. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004 Nov; 23 (11 Suppl.): S193-201
40. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991 Jun 1; 133 (11): 1135-51

41. Bradford JP, Bacharier LB, Bonfiglio J, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005 Jan; 115 (1): e7-14

42. Groskreutz DJ, Monick MM, Babor EC, et al. Cigarette smoke alters respiratory syncytial virus-induced apoptosis and replication. Am J Respir Cell Mol Biol 2009 Aug; 41 (2): 189-98

43. Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009 Oct; 14 (8): 521-32

44. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008 Jul-Aug; 28 (4): 471-80

45. Dowell SF, Anderson LJ, Gary Jr HE, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996 Sep; 174 (3): 456-62

46. Boyce JM, Pittet D. Guideline for Hand Hygiene in Healthcare Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002 12 (1): S3-40

47. Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis 2000 Aug; 31 (2): 590-6

48. Langleby JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study. Pediatrics 1997 Dec; 100 (6): 943-6

49. Groothuis J, Bauman J, Malinoski F, et al. Strategies for prevention of RSV nosocomial infection. J Perinatol 2008 May; 28 (5): 319-23

50. Isaacs D, Dickson H, O’Callaghan C, et al. Handwashing and cohorting in prevention of hospital acquired infections with respiratory syncytial virus. Arch Dis Child 1991 Feb; 66 (2): 227-31

51. Schiller O, Levy I, Pollak U, et al. Central apnoeas in infants with bronchiolitis admitted to the paediatric intensive care unit. Acta Paediatr 2010 Feb; 100 (2): 216-9

52. Paes BA, Mitchell I, Baneri J, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011 Mar-Apr; 18 (2): c10-9

53. Mitchell I. Treatment of RSV bronchiolitis: drugs, antibiotics. Paediatr Respir Rev 2009 Jun; 10 Suppl. 1: 14-5

54. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 2010 Feb; 125 (2): 342-9

55. Law BJ, Wang EE, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 1997 Mar; 99 (3): E7

56. Zhu Q, McAuliffe JM, Patel NK, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect. Dis 2011 Mar; 203: 674-82

57. Feltes TF, Sondheimer HM, Tulloh RMR, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011 Aug; 70 (2): 186-91

58. Group TI-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 1998 Sep; 102 (3): 531-7

59. Grimaldi M, Gouyon B, Sagot P, et al. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007 Mar; 42 (3): 189-92

60. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003 Sep; 22 (9): 823-7

61. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003 Oct; 143 (4): 532-40

62. Empey KM, Peebles Jr RS, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010 May 1; 50 (9): 1258-67

63. Orr P, McDonald S, Milley D, et al. Bronchiolitis in Inuit children from a Canadian central arctic community, 1995-1996. Int J Circumpolar Health 2001 Nov; 60 (4): 649-58

64. National Advisory Committee on Immunization. Canadian Immunization Form. 7th ed. Ottawa (ON): Publishing and Depository Services, Public Works and Government Services Canada, 2006

65. Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics 2004 Nov; 114 (5): e554-6

66. Simoes EA, Carbonell-Estrany X, Rieger CH, et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010 Aug; 126 (2): 256-62

67. Boyce TG, Mellen BG, Mitchell Jr EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000 Dec; 137 (6): 865-70

68. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006 Oct; 160 (10): 1070-6

69. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007; 25 (1): 55-71

70. Reeve CA, Whitehall JS, Buettnger PG, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006 May; 42 (5): 253-8

71. Lancéot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus
prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008 Nov; 24 (11): 3223-37

72. Paes B, Steele S, Janes M, et al. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009 Jul; 25 (7): 1585-91

73. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998 Jul; 11 (3): 430-9

74. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969 Apr; 89 (4): 422-34

75. Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Reports 2011 Apr; 44 (4): 232-7

Correspondence: Marianne Bracht, RN, Neonatal Intensive Care Unit, Mount Sinai Hospital, 775 A-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
E-mail: mbracht@mtsinai.on.ca